BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Husain AM, Ristanovic RK, Bogan RK. Weight loss in narcolepsy patients treated with sodium oxybate. Sleep Med 2009;10:661-3. [PMID: 19014899 DOI: 10.1016/j.sleep.2008.05.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Hassan Z, Bosch OG, Singh D, Narayanan S, Kasinather BV, Seifritz E, Kornhuber J, Quednow BB, Müller CP. Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs. Front Psychiatry 2017;8:152. [PMID: 28868040 DOI: 10.3389/fpsyt.2017.00152] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
2 Bosch OG, Seifritz E. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans. Brain Res Bull 2016;126:47-60. [PMID: 26855327 DOI: 10.1016/j.brainresbull.2016.02.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Medicine 2015;16:9-18. [DOI: 10.1016/j.sleep.2014.10.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 11.0] [Reference Citation Analysis]
4 Giorgetti A, Busardò FP, Giorgetti R. Toxicological Characterization of GHB as a Performance-Enhancing Drug. Front Psychiatry 2022;13:846983. [DOI: 10.3389/fpsyt.2022.846983] [Reference Citation Analysis]
5 Donjacour CE, Aziz NA, Overeem S, Kalsbeek A, Pijl H, Lammers GJ. Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep 2014;37:795-801. [PMID: 24899766 DOI: 10.5665/sleep.3592] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
6 Taddei RN, Werth E, Poryazova R, Baumann CR, Valko PO. Diagnostic delay in narcolepsy type 1: combining the patients' and the doctors' perspectives. J Sleep Res 2016;25:709-15. [DOI: 10.1111/jsr.12420] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
7 Schinkelshoek MS, Smolders IM, Donjacour CE, van der Meijden WP, van Zwet EW, Fronczek R, Lammers GJ. Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. J Sleep Res 2019;28:e12684. [PMID: 29504180 DOI: 10.1111/jsr.12684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Donjacour CE, Aziz NA, Roelfsema F, Frölich M, Overeem S, Lammers GJ, Pijl H. Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab 2011;300:E1069-75. [PMID: 21447786 DOI: 10.1152/ajpendo.00623.2010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
9 van Nieuwenhuijzen PS, Long LE, Hunt GE, Arnold JC, Mcgregor IS. Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology 2010;212:663-74. [DOI: 10.1007/s00213-010-1986-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics 2012;9:739-52. [PMID: 23065655 DOI: 10.1007/s13311-012-0150-9] [Cited by in Crossref: 121] [Cited by in F6Publishing: 81] [Article Influence: 13.4] [Reference Citation Analysis]
11 Thorpy MJ. Update on Therapy for Narcolepsy. Curr Treat Options Neurol 2015;17. [DOI: 10.1007/s11940-015-0347-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
12 Luca G, Vienne J, Vaucher A, Jimenez S, Tafti M. Central and peripheral metabolic changes induced by gamma-hydroxybutyrate. Sleep 2015;38:305-13. [PMID: 25515097 DOI: 10.5665/sleep.4420] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Alshaikh MK, Gacuan D, George S, Sharif M, Bahammam AS. Long-Term Follow-Up of Patients With Narcolepsy-Cataplexy Treated With Sodium Oxybate (Xyrem). Clinical Neuropharmacology 2011;34:1-4. [DOI: 10.1097/wnf.0b013e318203d415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Ponziani V, Pizza F, Zenesini C, Vignatelli L, Pession A, Plazzi G. BMI changes in pediatric type 1 narcolepsy under sodium oxybate treatment. Sleep 2021;44:zsaa295. [PMID: 33388769 DOI: 10.1093/sleep/zsaa295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mohammadi S, Moosaie F, Saghazadeh A, Mahmoudi M, Rezaei N. Metabolic profile in patients with narcolepsy: a systematic review and meta-analysis. Sleep Med 2021;81:268-84. [PMID: 33740593 DOI: 10.1016/j.sleep.2021.02.040] [Reference Citation Analysis]
16 Avidan AY, Kushida CA. The sodium in sodium oxybate: is there cause for concern? Sleep Med 2020;75:497-501. [PMID: 33022487 DOI: 10.1016/j.sleep.2020.09.017] [Reference Citation Analysis]
17 Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opinion on Pharmacotherapy 2017;18:809-17. [DOI: 10.1080/14656566.2017.1323877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
18 Mayer G. The use of sodium oxybate to treat narcolepsy. Expert Rev Neurother 2012;12:519-29. [PMID: 22550980 DOI: 10.1586/ern.12.42] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
19 Morse AM, Kelly-pieper K, Kothare SV. Management of Excessive Daytime Sleepiness in Narcolepsy With Baclofen. Pediatric Neurology 2019;93:39-42. [DOI: 10.1016/j.pediatrneurol.2018.10.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
20 Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol 2016;18. [DOI: 10.1007/s11940-016-0429-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
21 Donjacour CE, Pardi D, Aziz NA, Frölich M, Roelfsema F, Overeem S, Pijl H, Lammers GJ. Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy controls: basal concentrations and response to sodium oxybate. J Clin Sleep Med 2013;9:797-803. [PMID: 23946710 DOI: 10.5664/jcsm.2924] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
22 Noujaim MG, Mourad A, Clough JD. Sodium Oxybate: A Cause of Extreme Involuntary Weight Loss in a Young Lady. Case Rep Med 2019;2019:6537815. [PMID: 31428154 DOI: 10.1155/2019/6537815] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Johansson J, Grönbladh A, Hallberg M. Gamma-hydroxybutyrate (GHB) induces cognitive deficits and affects GABAB receptors and IGF-1 receptors in male rats. Behavioural Brain Research 2014;269:164-74. [DOI: 10.1016/j.bbr.2014.04.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
24 Pillen S, Pizza F, Dhondt K, Scammell TE, Overeem S. Cataplexy and Its Mimics: Clinical Recognition and Management. Curr Treat Options Neurol 2017;19:23. [PMID: 28478511 DOI: 10.1007/s11940-017-0459-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
25 Barateau L, Lopez R, Dauvilliers Y. Treatment Options for Narcolepsy. CNS Drugs 2016;30:369-79. [PMID: 27155860 DOI: 10.1007/s40263-016-0337-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
26 Akinnusi ME, Saliba R, Porhomayon J, El-Solh AA. Sleep disorders in morbid obesity. Eur J Intern Med 2012;23:219-26. [PMID: 22385877 DOI: 10.1016/j.ejim.2011.10.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]